[Resistant and progressive cutaneous lupus erythematosus treated with belimumab: A retrospective monocentric study]. / Lupus érythémateux cutanés réfractaires traités par bélimumab : étude descriptive monocentrique.
Rev Med Interne
; 41(3): 152-159, 2020 Mar.
Article
in Fr
| MEDLINE
| ID: mdl-31980188
ABSTRACT
BACKGROUND:
Belimumab is currently approved for the treatment of active systemic lupus erythematosus (SLE). The aim of our study was to evaluate the efficacy of belimumab in the treatment of cutaneous lupus erythematosus (CLE), resistant to conventional therapy. PATIENTS ANDMETHODS:
Seven patients with resistant and progressive LEC and treated with belimumab were retrospectively analyzed. The efficacy and safety of belimumab were evaluated with the CLASI, RCLASI and DLQI scores, after 6 to 12 months of treatment.RESULTS:
Eighty-three percent of patients demonstrated a significant clinical improvement based on the CLASI and RCLASI activity scores, including 1 complete and 4 partial responses, without worsening of CLASI and RCLASI damage scores. Eighty percent of patients also showed an improvement of their quality of life (DLQI). Oral corticosteroids were discontinued in all patients. Tolerance was acceptable with only one serious adverse event (bacteriema).CONCLUSION:
Our study suggests the clinical efficiency of belimumab in a series of 7 patients presenting a resistant and progressive CLE.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lupus Erythematosus, Cutaneous
/
Drug Resistance
/
Antibodies, Monoclonal, Humanized
/
Immunosuppressive Agents
Type of study:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Aspects:
Patient_preference
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Europa
Language:
Fr
Journal:
Rev Med Interne
Year:
2020
Document type:
Article